The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors
暂无分享,去创建一个
Christopher Southan | Stephen PH Alexander | Eamonn Kelly | John A Peters | Elena Faccenda | Adam J Pawson | Joanna L Sharman | Jamie A Davies | Neil Marrion | Helen E Benson | Stephen P. H. Alexander | Anthony P Davenport | C. Southan | N. Marrion | J. Davies | E. Faccenda | J. Sharman | A. Davenport | H. E. Benson | J. A. Peters | E. Kelly
[1] S. Liberles. Trace amine-associated receptors: ligands, neural circuits, and behaviors , 2015, Current Opinion in Neurobiology.
[2] A. Pioszak,et al. Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G Protein-Coupled Receptor , 2015, Molecular cell.
[3] Y. Yung,et al. Lysophosphatidic acid signalling in development , 2015, Development.
[4] Richard J. Edwards,et al. Metabotropic Glutamate Receptors , 2015, The Journal of Biological Chemistry.
[5] J. Chun,et al. LPA signaling initiates schizophrenia-like brain and behavioral changes in a mouse model of prenatal brain hemorrhage , 2015, Translational Psychiatry.
[6] Y. Yung,et al. Lysophosphatidic Acid Signaling in the Nervous System , 2015, Neuron.
[7] A. Russo. Calcitonin gene-related peptide (CGRP): a new target for migraine. , 2015, Annual review of pharmacology and toxicology.
[8] L. Devi,et al. Challenges for opioid receptor nomenclature: IUPHAR Review 9 , 2015, British journal of pharmacology.
[9] R. Glen,et al. Abstract 15352: ELABELA/Toddler, a Critical Regulator of Cardiac Development, is Expressed in the Human Cardiovascular System and Binds the Apelin Receptor , 2014 .
[10] J. Furness,et al. Novel and Conventional Receptors for Ghrelin, Desacyl-Ghrelin, and Pharmacologically Related Compounds , 2014, Pharmacological Reviews.
[11] D. Lambert,et al. Functional plasticity of the N/OFQ‐NOP receptor system determines analgesic properties of NOP receptor agonists , 2014, British journal of pharmacology.
[12] S. Spiegel,et al. Lysophospholipid receptor nomenclature review: IUPHAR Review 8 , 2014, British journal of pharmacology.
[13] Y. Yung,et al. LPA receptor signaling: pharmacology, physiology, and pathophysiology , 2014, Journal of Lipid Research.
[14] Jay Halai. Behaviour management: Creating the right climate for learning , 2014 .
[15] A. Lehmann,et al. Fine‐tuning somatostatin receptor signalling by agonist‐selective phosphorylation and dephosphorylation: IUPHAR Review 5 , 2014, British journal of pharmacology.
[16] R. Mechoulam,et al. The endocannabinoid system and the brain. , 2013, Annual review of psychology.
[17] M. von Zastrow,et al. Regulation of µ-Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance , 2013, Pharmacological Reviews.
[18] R. Jensen,et al. Bombesin-Related Peptides , 2013 .
[19] R. Summers,et al. Relaxin family peptides and their receptors. , 2013, Physiological reviews.
[20] K. Ressler,et al. Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y , 2012, Physiology & Behavior.
[21] M. Knepper. Systems biology in physiology: the vasopressin signaling network in kidney. , 2012, American journal of physiology. Cell physiology.
[22] R. Barker,et al. Neuropeptide Y and its role in CNS disease and repair , 2012, Experimental Neurology.
[23] R. Landgraf,et al. Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors , 2012, Trends in Neurosciences.
[24] E. Butelman,et al. κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction , 2012, Trends in Neurosciences.
[25] A. Schober,et al. Lysophosphatidic acid in atherosclerotic diseases , 2012, British journal of pharmacology.
[26] Taka-aki Koshimizu,et al. Vasopressin V1a and V1b receptors: from molecules to physiological systems. , 2012, Physiological reviews.
[27] G. Burnstock,et al. Purinergic Signalling and the Nervous System , 2012, Springer Berlin Heidelberg.
[28] B. Slusher,et al. Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting. , 2012, European journal of pharmacology.
[29] L. Eiden,et al. Is PACAP the Major Neurotransmitter for Stress Transduction at the Adrenomedullary Synapse? , 2012, Journal of Molecular Neuroscience.
[30] C. Salvatore,et al. Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine , 2012, British journal of pharmacology.
[31] H. Vaudry,et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide: IUPHAR Review 1 , 2012, British journal of pharmacology.
[32] J. Archbold,et al. Calcitonin and calcitonin receptor‐like receptors: common themes with family B GPCRs? , 2012, British journal of pharmacology.
[33] R. Quirion,et al. The pharmacology of Adrenomedullin 2/Intermedin , 2012, British journal of pharmacology.
[34] U. Plöckinger. Medical Therapy of Acromegaly , 2012, International journal of endocrinology.
[35] A. Tamas,et al. Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney , 2012, Neuropeptides.
[36] G. Guillon,et al. Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics , 2012, Journal of neuroendocrinology.
[37] S. Peineau,et al. Molecular mechanisms of somatostatin receptor trafficking. , 2012, Journal of molecular endocrinology.
[38] J. Chun,et al. Insights into the pharmacological relevance of lysophospholipid receptors , 2012, British journal of pharmacology.
[39] Peter Kirsch,et al. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine , 2011, Nature Reviews Neuroscience.
[40] R. Hampson,et al. Endocannabinoid tone versus constitutive activity of cannabinoid receptors , 2011, British journal of pharmacology.
[41] Lei Zhang,et al. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. , 2011, Pharmacology & therapeutics.
[42] N. Bolger,et al. Social effects of oxytocin in humans: context and person matter , 2011, Trends in Cognitive Sciences.
[43] F. Xu. Synthesis of Telcagepant , 2011 .
[44] R. Ivell,et al. Relaxin family peptides in the male reproductive system--a critical appraisal. , 2011, Molecular human reproduction.
[45] Z. Andrews. The extra-hypothalamic actions of ghrelin on neuronal function , 2011, Trends in Neurosciences.
[46] Xiuxia Liu,et al. Prostaglandin E receptors as inflammatory therapeutic targets for atherosclerosis. , 2011, Life sciences.
[47] S. Leeman,et al. Neurokinin‐1 receptor: functional significance in the immune system in reference to selected infections and inflammation , 2011, Annals of the New York Academy of Sciences.
[48] N. Rance,et al. Neurokinin B and the hypothalamic regulation of reproduction , 2010, Brain Research.
[49] P. Georgoulias,et al. Current and potential roles of ghrelin in clinical practice , 2010, Journal of endocrinological investigation.
[50] Z. Andrews,et al. Metabolic Status Regulates Ghrelin Function on Energy Homeostasis , 2010, Neuroendocrinology.
[51] Sarah Spiegel,et al. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature , 2010, Pharmacological Reviews.
[52] Stuart Maudsley,et al. The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders. , 2010, CNS & neurological disorders drug targets.
[53] E. Ghigo,et al. Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. , 2010, Journal of molecular endocrinology.
[54] G. Kouraklis,et al. Ghrelin: A potential therapeutic target for cancer , 2010, Regulatory Peptides.
[55] T. Comery,et al. SAM-531, N,N-dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy} propan-1-amine, a novel serotonin-6 receptor antagonist with preclinical pro-cognitive efficacy , 2010, Alzheimer's & Dementia.
[56] A. Zengin,et al. Neuropeptide Y and sex hormone interactions in humoral and neuronal regulation of bone and fat , 2010, Trends in Endocrinology & Metabolism.
[57] Michael R Dores,et al. Signal transduction by protease‐activated receptors , 2010, British journal of pharmacology.
[58] P. Vanhoutte,et al. The thromboxane/endoperoxide receptor (TP): the common villain. , 2010, Journal of cardiovascular pharmacology.
[59] G. E. Callander,et al. Relaxin family peptide systems and the central nervous system , 2010, Cellular and Molecular Life Sciences.
[60] R. Quirion,et al. A possible role of neuropeptide Y in depression and stress , 2010, Brain Research.
[61] K. Commons. Neuronal pathways linking substance P to drug addiction and stress , 2010, Brain Research.
[62] Willem van der Westhuizen,et al. Power station pump selection: part 2 , 2010 .
[63] K. Jacobson,et al. Adenosine A3 Receptors in Muscle Protection , 2010 .
[64] Ross A. D. Bathgate,et al. Cardiovascular effects of relaxin: from basic science to clinical therapy , 2010, Nature Reviews Cardiology.
[65] I. Depoortere,et al. Motilin and ghrelin as prokinetic drug targets. , 2009, Pharmacology & therapeutics.
[66] T. Sotnikova,et al. Trace Amine-Associated Receptors as Emerging Therapeutic Targets , 2009, Molecular Pharmacology.
[67] S. Douglas,et al. Neurokinin 1 receptor isoforms and the control of innate immunity. , 2009, Trends in immunology.
[68] Takao Shimizu,et al. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. , 2009, Annual review of pharmacology and toxicology.
[69] V. Georgiev,et al. Drug Development Research , 2009, National Institute of Allergy and Infectious Diseases, NIH.
[70] M. Zatelli,et al. The significance of new somatostatin analogs as therapeutic agents. , 2009, Current opinion in investigational drugs.
[71] R. Quirion,et al. International Union of Pharmacology. LXIX. Status of the Calcitonin Gene-Related Peptide Subtype 2 Receptor , 2008, Pharmacological Reviews.
[72] K. Dezaki,et al. Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. , 2008, Pharmacology & therapeutics.
[73] S. O'Sullivan,et al. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors , 2007, British journal of pharmacology.
[74] K. Sullivan. A royal charter , 2007 .
[75] M. Glass,et al. Meta‐analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences , 2007, British journal of pharmacology.
[76] Stephen P. H. Alexander,et al. The complications of promiscuity: endocannabinoid action and metabolism , 2007, British journal of pharmacology.
[77] C. Delporte,et al. Influence of ghrelin on food intake and energy homeostasis , 2007, Current opinion in clinical nutrition and metabolic care.
[78] S. Petrosino,et al. Endocannabinoids and the regulation of their levels in health and disease , 2007, Current opinion in lipidology.
[79] W. Froestl,et al. Chemistry of GABAB Modulators , 2007 .
[80] G. Chiellini,et al. Trace amine‐associated receptors and their ligands , 2006, British journal of pharmacology.
[81] R. Ivell,et al. International Union of Pharmacology LVII: Recommendations for the Nomenclature of Receptors for Relaxin Family Peptides , 2006, Pharmacological Reviews.
[82] Cheryl L. Morse,et al. Automated radiosynthesis of [18F]SPA-RQ for imaging human brain NK1 receptors with PET , 2006 .
[83] T. Bártfai,et al. M871—A Novel Peptide Antagonist Selectively Recognizing the Galanin Receptor Type 2 , 2006, International Journal of Peptide Research and Therapeutics.
[84] R. Neubig,et al. International Union of Pharmacology. LVI. Ghrelin Receptor Nomenclature, Distribution, and Function , 2005, Pharmacological Reviews.
[85] Richard R. Neubig,et al. International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List , 2005, Pharmacological Reviews.
[86] D. Millar. Taking the Initiative , 2005 .
[87] J. Kukkonen,et al. Intracellular Signal Pathways Utilized by the Hypocretin/Orexin Receptors , 2005 .
[88] F. Marceau,et al. Bradykinin receptor ligands: therapeutic perspectives , 2004, Nature Reviews Drug Discovery.
[89] L. Clozel. Combinatorial consequences of Arthur's conjectures and the Burger-Sarnak method , 2004 .
[90] K. Payza. Binding and Activity of Opioid Ligands at the Cloned Human Delta, Mu, and Kappa Receptors , 2003 .
[91] Patrick M. Sexton,et al. International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors , 2002, Pharmacological Reviews.
[92] Barry Anderson,et al. A guide to modern science : science and technology in today's world / Barry Anderson ... [et al.] ; consultant editor, Wilson Da Silva. , 2002 .
[93] P. Seeman. Antipsychotic drugs, dopamine receptors, and schizophrenia , 2001, Clinical Neuroscience Research.
[94] R. Breton. Les langues non-tatiques dEurope: relev gopolitique et dmographique , 2001 .
[95] G. Guillon,et al. Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. , 2000, Kidney international.
[96] G. Camussi,et al. Role of platelet-activating factor in cardiovascular pathophysiology. , 2000, Physiological reviews.
[97] S. Ishii,et al. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. , 2000, Progress in lipid research.
[98] K. Jacobson,et al. 1,3‐dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors , 1999, Drug development research.
[99] D. Pruneau,et al. Pharmacological characterization of the bradykinin B2 receptor: inter‐species variability and dissociation between binding and functional responses , 1999, British journal of pharmacology.
[100] S. Rawlings,et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. , 1998, Pharmacological reviews.
[101] H Herzog,et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. , 1998, Pharmacological reviews.
[102] J. F. Brown,et al. Role of mast cells, neutrophils and nitric oxide in endotoxin‐induced damage to the neonatal rat colon , 1998, British journal of pharmacology.
[103] P. Jj. Le jaune d'oeuf, une cible pour les salmonelles , 1997 .
[104] G. Mcallister,et al. 5-HT1E and 5-HT1F receptors , 1997 .
[105] P. Braquet,et al. Platelet-activating factor antagonists , 1995, Clinical Reviews in Allergy.
[106] J. Macor,et al. Biochemical and behavioral studies of the 5‐HT1B receptor agonist, CP‐94,253 , 1992 .
[107] F. Snyder. Platelet-Activating Factor and Related Lipid Mediators , 1987, Springer US.
[108] B Fisher,et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. , 1985, The New England journal of medicine.
[109] J. Reubi,et al. Somatostatin Receptors , 1997, Trends in Endocrinology & Metabolism.
[110] H. Maeno,et al. Dopamine Receptors , 2018 .